viewIncanthera plc

Incanthera debuts on Nex Exchange and starts partner search for novel cancer treatment

The aim is to find a commercial partner for Sol within 12-18 months.

Incanthera Ltd -
Incanthera expects a lot of interest from cosmetics firms

Incanthera PLC (LON:INC) started trading on the NEX Exchange Growth market today after raising £1.2mln to fund the development of its novel cream to treat and prevent skin cancer.

Called Sol, the cream has already gone through the proof of concept stage and Incanthera now wants a partner for the development and marketing stages.

Simon Ward, founder and chief executive, believes Sol has huge potential in both the therapeutic and cosmetic markets, where it can help remove Solar Keratoses, which are a common cause of skin cancer, as well as being a preventative application.

Originally a spin-out from Bradford University’s Institute of Cancer Therapeutics, the aim is to find a commercial partner for Sol within 12-18 months.

Incanthera has also rights to a portfolio of ICT’s other cancer-targeting therapeutics and will use partnerships to take other candidates from this portfolio to market.

The technology uses a proprietary formulation and prodrug targeting technologies to deliver treatment specifically to the tumour.

Prodrugs only become active when they reach a target, so are less toxic and enabling higher doses to reach a target and therefore increase efficacy.

Ward added: “Cancer is one of the world's most pressing health challenges.

“There is a clear unmet clinical need for developing targeted oncology medicines that are effective against tumours whilst avoiding harsh systemic side effects and we believe that our unique strategy offers one of the most promising approaches.”

Aim-listed biotech Immupharma PLC (LON:IMM) has an 11.9% stake and warrants at the listing price of 9.5p plus an option to subscribe for a further £250,000 worth of shares by end October.

Quick facts: Incanthera plc

Price: 17 GBX

Market: AQSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Incanthera plc named herein, including the promotion by the Company of Incanthera plc in any Content on the Site, the Company receives from...


Incanthera says development of skin cancer asset Sol has gone 'way beyond...

Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive following the release of their interim results for the six months ended 30 September 2020. McCarthy explains how it has been a 'pivotal year' for the company and says they're now fully focused on further development of its...

on 8/12/20

2 min read